# Autologous CD4+ antigen-specific T-cell clones in advanced ovarian or primary peritoneal cancer (Fred Hutchinson phase 1)

Source: https://onco.cc/trials/nct00101257/  
OnCo record `nct00101257` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Seattle safety and dose trial of helper T cells grown from patients' own blood, in women with advanced ovarian or peritoneal cancer. It ran from 2004 to 2010.

## Summary

The registry describes a phase I study of the side effects and best dose of autologous CD4+ antigen-specific T-cell clones in stage III or IV ovarian or primary peritoneal cancer, started in October 2004 and completed in March 2010, with an estimated enrolment of 18 (ClinicalTrials.gov NCT00101257). Cassian Yee is listed as study chair and Fred Hutchinson Cancer Center as sponsor (ClinicalTrials.gov NCT00101257). No results are posted.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-05
- Registry id: NCT00101257
- Phase: 1
- Setting: Stage III or IV ovarian cancer or primary peritoneal cancer: autologous CD4+ antigen-specific T-cell clones
- Sponsor: Fred Hutchinson Cancer Center
- Result: No results posted on ClinicalTrials.gov.

## Sources

- ClinicalTrials.gov NCT00101257: https://clinicaltrials.gov/study/NCT00101257

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- institutions: [Fred Hutchinson Cancer Center](https://onco.cc/institutions/fred-hutch/)
- terms: [Endogenous T-cell therapy](https://onco.cc/terms/endogenous-t-cell-therapy/)
- people: [Cassian Yee](https://onco.cc/people/cassian-yee/)

---
JSON: https://onco.cc/api/v1/entities/nct00101257.json